An update on ripasudil for the treatment of glaucoma and ocular hypertension

V. Testa, Lorenzo Ferro Desideri, P. Della Giustina, C. E. Traverso, M. Iester

Research output: Contribution to journalArticlepeer-review


Ripasudil (K-115) is a novel Rho-associated protein kinase (ROCK) inhibitor. The Rho-ROCK pathway regulates key downstream effectors involved in many cellular functions, in particular in the actin cytoskeleton activity. The clinical effects of ripasudil expected on the eye include an intraocular pressure-lowering effect and a wound-healing activity on corneal endothelial cells, but many other functions are currently under investigation. To date, ripasudil has been approved in Japan (2014) for the treatment of glaucoma and ocular hypertension, and several clinical trials are currently investigating its role in the treatment of Fuchs’ corneal dystrophy. In this review, we will discuss its pharmacokinetics, pharmacodynamics and clinical efficacy, focusing also on its safety and tolerability profile.

Original languageEnglish
Pages (from-to)599-608
Number of pages10
JournalDrugs of Today
Issue number9
Publication statusPublished - Sep 2020


  • Glaucoma
  • Ocular hypertension
  • Ophthalmic drugs
  • Rho-associated protein kinase (ROCK) inhibitors
  • Ripasudil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'An update on ripasudil for the treatment of glaucoma and ocular hypertension'. Together they form a unique fingerprint.

Cite this